Mast Therapeutics Inc (MSTX) Short Interest Update
Mast Therapeutics Inc (NYSE:MSTX) was the recipient of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 7,102,740 shares, a growth of 12.9% from the October 31st total of 6,290,337 shares. Based on an average daily trading volume, of 4,295,436 shares, the short-interest ratio is currently 1.7 days. Currently, 3.4% of the company’s stock are short sold.
Shares of Mast Therapeutics (NYSE:MSTX) opened at 0.0929 on Wednesday. The stock has a 50 day moving average of $0.08 and a 200 day moving average of $0.31. Mast Therapeutics has a 1-year low of $0.07 and a 1-year high of $0.71. The firm’s market cap is $22.13 million.
Mast Therapeutics (NYSE:MSTX) last posted its earnings results on Tuesday, November 8th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. Equities research analysts anticipate that Mast Therapeutics will post ($0.19) earnings per share for the current fiscal year.
A number of research firms recently commented on MSTX. Laidlaw downgraded shares of Mast Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 21st. Maxim Group set a $5.00 target price on shares of Mast Therapeutics and gave the company a “buy” rating in a research report on Thursday, September 8th. Zacks Investment Research cut shares of Mast Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 12th. Cowen and Company cut shares of Mast Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Friday, September 23rd. Finally, S&P Equity Research increased their price target on shares of Mast Therapeutics from $0.08 to $0.09 in a research note on Friday, October 14th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Mast Therapeutics currently has an average rating of “Hold” and a consensus target price of $2.07.
Mast Therapeutics Company Profile
Mast Therapeutics, Inc is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options.
Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.